EKF Diagnostics

What EKF Diagnostics does

EKF Diagnostics Holdings plc is a UK-domiciled, AIM-listed (LSE: EKF) global diagnostics and biotechnology company founded in 1990 and headquartered in Cardiff, Wales. The company develops, manufactures, and distributes point-of-care in-vitro diagnostic devices and life sciences products through wholly-owned operating subsidiaries including Stanbio Laboratory LLC (US, Boerne, TX), EKF-diagnostic GmbH (Germany), and Separation Technology Inc. EKF's product portfolio spans point-of-care hematology analyzers (DiaSpect Tm, Hemo Control, HemataStat II), diabetes management systems (Biosen C-Line, Quo-Test, Quo-Lab, STAT-Site WB), women's health tests (Creamatocrit Plus, QuPID, True 20), sports performance analyzers (Lactate Scout Sport), veterinary diagnostics (Lactate Scout Vet, Hemo Vet), central laboratory reagents and immunoassays (Beta-Hydroxybutyrate LiquiColor, RaPET, QuStick), molecular transport media (PrimeStore), and specialty diagnostic enzymes (Arylacylamidase, Beta-Hydroxybutyrate Dehydrogenase, Salicylate Hydroxylase). The proprietary EKF Link platform integrates point-of-care devices with hospital and laboratory IT systems for real-time data and device management.

EKF's revenue model is predominantly hardware-and-consumable sales (analyzer devices plus recurring cuvettes, reagents, and enzymes), supplemented by contract reagent manufacturing services and (post-ADL Health acquisition) COVID-19 molecular diagnostic testing services. The company distributes to over 120 countries through authorized medical supply dealers, direct distribution, and channel partners, with manufacturing sites on two continents providing regulatory and logistical reach. Group purchasing agreements such as the Blood Centers of America deal provide anchor enterprise channels, while long-tail distribution and a partner portal extend mid-market reach. Reported FY2025 revenue was £51.6M with £7.1M pre-tax profit and 51% gross margin in H2 2025, representing 3% year-over-year growth.

The company is executing a stated five-year strategic plan anchored by selective acquisitions, including Intelligent Ultrasound Group plc (February 2025) and Beep Insights AB technology assets (April 2026), to extend into adjacent medical imaging and AI-enabled sports performance verticals. Christopher Mills (Non-Executive Director) controls approximately 29.49% of voting rights through investment entities. The company is ISO 13485 and ISO 9001 certified across multiple jurisdictions and complies with AIM listing requirements, including share buyback activity to maintain the controlling stake below the 30% mandatory offer threshold.

Name

EKF Diagnostics

Legal name

EKF Diagnostics Holdings plc

Website

https://ekfdiagnostics.com

Company type

Public

Founded year

1990

Operating status

Operating

Headcount range

101–250 employees

Short description

EKF Diagnostics Holdings plc is a UK-headquartered, AIM-listed global diagnostics company manufacturing point-of-care in-vitro diagnostic devices (hematology, diabetes, women's health, sports, veterinary), central laboratory reagents, and specialty diagnostic enzymes from US and German facilities, distributing to 120+ countries across healthcare, biotech, and life sciences customers.

Ownership category

akta.pro rank

Product category

Point-of-Care In-Vitro Diagnostics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), In-Vitro Diagnostic Substance Manufacturing (325413), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)

akta.pro secondary industries

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL), Reference Laboratory Testing (Clinical Pathology & Chemistry) (HLAMADAA), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK)

Keywords

• Point-of-care diagnostics
• In-vitro diagnostic devices
• Clinical chemistry reagents
• Diagnostic enzymes manufacturing
• Hematology analyzers

Headquarters

HQ city

Vale of Glamorgan

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Point-of-Care Diagnostic Devices: Sale of medical devices and tests for point-of-care testing including hematology, diabetes, women's health, sports performance, and veterinary analyzers
2. Life Sciences Products: Reagents, enzymes, and components for research, biotechnology, and pharmaceutical industries
3. Central Laboratory Products: Devices, tests, and media for high-throughput central laboratory analysis including reagents, immunoassays, and transport media
4. Contract Manufacturing Services: Contract reagent services including reagent formulation and kitting for healthcare partners

Go-to-market motion2 records

Distribution channels4 records

Marketing channels3 records

Core offering

EKF Diagnostics manufactures and distributes point-of-care in-vitro diagnostic devices and tests for hematology, diabetes, women's health, sports performance, and veterinary applications, alongside central laboratory reagents and life sciences diagnostic enzymes. The company also supplies the EKF Link IT platform connecting point-of-care analyzers to hospital and laboratory information systems. Products are manufactured at facilities in the USA and Germany and sold to healthcare providers, blood centers, life sciences companies, and authorized dealers in over 120 countries.

Product overview

EKF Diagnostics is a global diagnostics and biotechnology company offering point-of-care in-vitro diagnostic devices and tests alongside life sciences products. The portfolio includes point-of-care analyzers for hematology (DiaSpect Tm, Hemo Control, HemataStat II), diabetes management (Biosen C-Line, Quo-Test, Quo-Lab, STAT-Site WB), women's health (Creamatocrit Plus, QuPID, True 20), and sports/veterinary applications (Lactate Scout Sport, Lactate Scout Vet, Hemo Vet). The connectivity platform EKF Link enables integration with hospital IT systems. Central laboratory offerings comprise reagents (Beta-Hydroxybutyrate LiquiColor), immunoassays (RaPET), infectious disease tests (QuStick), occult blood tests (Hema-Screen), transport media (PrimeStore), and analyzers (Uri-Trak 120M). Life sciences products include precision fermentation services, diagnostic enzymes (Arylaclamidase, Beta-Hydroxybutyrate Dehydrogenase, Salicylate Hydroxylase), and contract reagent manufacturing. Manufacturing facilities are located in the USA and Germany, with products distributed to over 120 countries worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• DiaSpect Tm

Quantifiable outcome

• 3% revenue increase in 2025
• +3 more outcomes

Named customers2 records

Segments7 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Blood Centers of AmericacoreChannel Partner/ Reseller/ Distributor · 3 March 2026EKF Diagnostics signed a three-year group purchasing agreement with Blood Centers of America, gaining access to more than 60 independent community blood centers across the US. Under the deal, EKF will supply its DiaSpect Tm hand-held haemoglobin analyser, consumable cuvettes, and the EKF Link IT system for quality control and data management. This agreement is a significant milestone in the company's five-year strategic plan to become the global leader in point-of-care hematology testing.
• Intelligent Ultrasound Group plccoreStrategic or Co-development Partner · 1 February 2025EKF Diagnostics acquired Intelligent Ultrasound Group plc in February 2025. CFO Helen Jones will oversee post-acquisition integration as the company executes its five-year development plan for accelerated growth.
• Advanced Diagnostic Laboratory LLC (ADL Health)minorStrategic or Co-development Partner · 11 November 2021EKF Diagnostics acquired Advanced Diagnostic Laboratory LLC (ADL Health), a Texas-based molecular diagnostics testing laboratory, specializing in COVID-19 testing for corporate, government, and travel sectors, providing rapid and accurate results including through high throughput PCR testing.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• HemoCue (Danaher): Direct competitor in point-of-care hemoglobin testing. HemoCue's handheld Hb analyzers and microcuvettes compete head-to-head with EKF's DiaSpect Tm in blood banks, anemia screening, and primary care settings globally.
• Nova Biomedical: Direct peer in hospital-grade POC glucose and lactate analyzers; Nova's StatStrip and Lactate Plus overlap with EKF's Biosen C-Line and Lactate Scout Sport, and the company serves the same clinical and sports performance segments.
• Trinity Biotech: AIM/Nasdaq-listed POC diagnostics peer focused on HbA1c and hemoglobin diagnostics; Trinity's Ultra2 and Premier Hb9210 analyzers compete directly with EKF's Quo-Test, Quo-Lab, and Hemo Control product lines.
• ARKRAY: Japanese POC diagnostics manufacturer with overlapping HbA1c and urine analytics portfolio (Quotation series) that competes with EKF's Quo-Test/Quo-Lab HbA1c analyzers globally.
• PTS Diagnostics (Trividia Health): POC diagnostics company selling HbA1c (A1cNow+) and lipid/CRP panels with overlapping customers and channels in primary care and pharmacy settings; competes with EKF's Quo-Lab and STAT-Site product lines.

Broad incumbents

• Siemens Healthineers (POC): Large incumbent with a broad POC and central-lab diagnostics portfolio including blood gas, HbA1c, and urine analyzers that overlap with EKF's Uri-Trak 120M, Quo-Test, and central lab reagents.
• Abbott Point of Care: Broader POC diagnostics incumbent (i-STAT, FreeStyle Libre) competing with EKF in glucose, lactate, and decentralized hospital testing; serves the same clinician customer base with greater commercial reach.
• QuidelOrtho: Broad infectious disease and rapid diagnostics player whose Sofia and Triage product lines overlap with EKF's central laboratory infectious disease and immunoassay products (QuStick, RaPET, Hema-Screen).
• GE HealthCare (Ultrasound): Adjacent peer through EKF's recent acquisition of Intelligent Ultrasound Group; GE competes in clinical ultrasound simulation and AI-enabled imaging — a category EKF is now exposed to post-acquisition.

Emerging players

• Sinocare: Chinese POC blood glucose leader expanding into HbA1c and lactate; overlaps with EKF's diabetes and lactate franchises in price-sensitive global markets and represents a low-cost competitive threat.

Market position

Weaknesses1 record

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/EKFdiagnostics
• Facebookfacebook.com/ekfdiagnostics
• LinkedInlinkedin.com/company/ekf-diagnostics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A9 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EKF Diagnostics